170 related articles for article (PubMed ID: 11966495)
1. Hiatal hernia is the key factor determining the lansoprazole dosage required for effective intra-oesophageal acid suppression.
Frazzoni M; De Micheli E; Grisendi A; Savarino V
Aliment Pharmacol Ther; 2002 May; 16(5):881-6. PubMed ID: 11966495
[TBL] [Abstract][Full Text] [Related]
2. Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole.
Frazzoni M; De Micheli E; Grisendi A; Savarino V
Aliment Pharmacol Ther; 2003 Jan; 17(2):235-41. PubMed ID: 12534408
[TBL] [Abstract][Full Text] [Related]
3. Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: a pH-metric comparison.
Frazzoni M; De Micheli E; Grisendi A; Savarino V
Aliment Pharmacol Ther; 2002 Jan; 16(1):35-9. PubMed ID: 11856076
[TBL] [Abstract][Full Text] [Related]
4. Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood.
Franco MT; Salvia G; Terrin G; Spadaro R; De Rosa I; Iula VD; Cucchiara S
Dig Liver Dis; 2000 Nov; 32(8):660-6. PubMed ID: 11142573
[TBL] [Abstract][Full Text] [Related]
5. Speed of onset of oesophageal acid reduction with different proton-pump inhibitors in patients with reflux oesophagitis.
Newton M; Burnham WR; Kamm MA
Eur J Gastroenterol Hepatol; 1998 Sep; 10(9):753-8. PubMed ID: 9831269
[TBL] [Abstract][Full Text] [Related]
6. Laparoscopic fundoplication versus lansoprazole for gastro-oesophageal reflux disease. A pH-metric comparison.
Frazzoni M; Grisendi A; Lanzani A; Melotti G; De Micheli E
Dig Liver Dis; 2002 Feb; 34(2):99-104. PubMed ID: 11926567
[TBL] [Abstract][Full Text] [Related]
7. Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole.
Frazzoni M; Manno M; De Micheli E; Savarino V
Dig Liver Dis; 2006 Feb; 38(2):85-90. PubMed ID: 16289976
[TBL] [Abstract][Full Text] [Related]
8. Ninety-six-hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients.
Calabrese C; Liguori G; Gabusi V; Gionchetti P; Rizzello F; Straforini G; Brugnera R; Di Febo G
Aliment Pharmacol Ther; 2008 Jul; 28(2):250-5. PubMed ID: 18485128
[TBL] [Abstract][Full Text] [Related]
9. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole.
Katz PO; Hatlebakk JG; Castell DO
Aliment Pharmacol Ther; 2000 Jun; 14(6):709-14. PubMed ID: 10848653
[TBL] [Abstract][Full Text] [Related]
10. Double-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15 mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux disease.
Wong WM; Lai KC; Hui WM; Lam KF; Huang JQ; Hu WH; Wong NY; Lam CL; Xia HH; Chan AO; Lam SK; Wong BC
Aliment Pharmacol Ther; 2004 Feb; 19(4):455-62. PubMed ID: 14871286
[TBL] [Abstract][Full Text] [Related]
11. A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis.
Jaspersen D; Diehl KL; Schoeppner H; Geyer P; Martens E
Aliment Pharmacol Ther; 1998 Jan; 12(1):49-52. PubMed ID: 9692700
[TBL] [Abstract][Full Text] [Related]
12. Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus.
Wani S; Sampliner RE; Weston AP; Mathur S; Hall M; Higbee A; Sharma P
Aliment Pharmacol Ther; 2005 Oct; 22(7):627-33. PubMed ID: 16181302
[TBL] [Abstract][Full Text] [Related]
13. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors.
Katz PO; Anderson C; Khoury R; Castell DO
Aliment Pharmacol Ther; 1998 Dec; 12(12):1231-4. PubMed ID: 9882031
[TBL] [Abstract][Full Text] [Related]
14. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Röhss K; Lind T; Wilder-Smith C
Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
[TBL] [Abstract][Full Text] [Related]
15. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial.
Bautista J; Fullerton H; Briseno M; Cui H; Fass R
Aliment Pharmacol Ther; 2004 May; 19(10):1123-30. PubMed ID: 15142202
[TBL] [Abstract][Full Text] [Related]
16. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy.
Nzeako UC; Murray JA
Aliment Pharmacol Ther; 2002 Jul; 16(7):1309-16. PubMed ID: 12144581
[TBL] [Abstract][Full Text] [Related]
17. Dose-response relationship of lansoprazole to gastric acid antisecretory effects.
Blum RA; Hunt RH; Kidd SL; Shi H; Jennings DE; Greski-Rose PA
Aliment Pharmacol Ther; 1998 Apr; 12(4):321-7. PubMed ID: 9690720
[TBL] [Abstract][Full Text] [Related]
18. A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease.
Johnson DA; Stacy T; Ryan M; Wootton T; Willis J; Hornbuckle K; Brooks W; Doviak M
Aliment Pharmacol Ther; 2005 Jul; 22(2):129-34. PubMed ID: 16011671
[TBL] [Abstract][Full Text] [Related]
19. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.
Fujiwara Y; Higuchi K; Nebiki H; Chono S; Uno H; Kitada K; Satoh H; Nakagawa K; Kobayashi K; Tominaga K; Watanabe T; Oshitani N; Arakawa T
Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():10-8. PubMed ID: 15943841
[TBL] [Abstract][Full Text] [Related]
20. Proton pump inhibitors or surgery for gastro-oesophageal reflux disease.
Hinder RA
Dig Liver Dis; 2002 Feb; 34(2):95-6. PubMed ID: 11926565
[No Abstract] [Full Text] [Related]
[Next] [New Search]
